Updated on 6 January 2014
What were the biggest hits and misses of 2013?
Asia attracted a lot of interest from foreign multinational giants in the year 2013. This not only led to the increase in the number of acquisitions and mergers (M&A), it also led to a rise in investments and joint ventures. BioSpectrum has launched its special feature with a round up of all that happened in the last 12 months and presents Flashback 2013.
This elaborate feature has all the hits and misses of the year from the Asian life sciences industry, the path breaking products and ground breaking medical devices that made it to the top five in Asia through the year. Furthermore, the special report features a roundup of 2013's highlights from India, Malaysia, Taiwan, Thailand, Australia, Korea, Singapore, Malaysia and other prominent countries from the APAC region.
All the burning issues, starting from the biggest settlement ever made to the US drug regulator, the Food and Drug Administration (FDA), over quality issues of drugs; the darkest revelation of the year in the drug business - GlaxoSmithKline's corrupt actions in China; and the landmark verdict of the year that had the US Supreme Court declare that 'Human Genes cannot be Patented' have been covered elaborately in this feature.
BioSpectrum brings to its readers, 2013's bests and hall of shame in its special issue. Click below on the links to read on:
The 2013 Nobel in Medicine goes to...
Dr James E Rothman, Dr Randy W Schekman and Dr Thomas C Südhof have been jointly awarded the 2013 Nobel Prize in Physiology or Medicine for discovering the molecular principles and machinery that govern the regulation of vesicular traffic system in human cells.
Quintiles shuts down India phase I unit
Global CRO Quintiles has shut down its phase I unit in Hyderabad, India citing a ‘challenging external business environment'.
Dr Rongxiang Xu bags patent for Potential Regenerative Cell
Dr Rongxiang Xu's invention Potential Regenerative Cell (PRC), gets patent from State Intellectual Property Office of China (SIPO). PRCs are adult tissue cells that convert to the functional state of pluripotent stem cells.
Eli Lilly scientists accused of leaking trade secrets
Federal court documents have revealed accusations against two former Eli Lilly scientists from China for divulging $55 million in trade secrets to a rival Chinese pharmaceutical company.
Indian pharma receives highest ever FDI
As per the latest data released by the Indian Department of Industrial Policy and Promotion (DIPP), India's pharmaceutical sector received highest Foreign Direct Investment during April-June 2013.
China probes Bayer for unfair competition
A local branch of China's State Administration for Industry and Commerce (SAIC) is probing Bayer China for a potential case of unfair competition.